Western drugmakers aren’t the only ones building new plants in China. Taiwan’s ScinoPharm has just finished up a $113 million facility to make active pharmaceutical ingredients (APIs) for China, as well as for export to the U.S. and Europe.
Filed under: COMPANIES Tagged: API, ScinoPharm
